CSL Ltd - Company Profile
Powered by
All the data and insights you need on CSL Ltd in one report.
- Save hours of research time and resources with
our up-to-date CSL Ltd Strategy Report
- Understand CSL Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
CSL Catalyst Calendar
Proactively evaluate CSL Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of CSL Catalyst Calendar data
Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
---|---|---|---|---|---|---|---|
01 Dec 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
18 Nov 2019 | Phase II Trial Results | Clinipace Worldwide Inc; Sanifit Therapeutics SA | - | SNF-472 | Cardiovascular; Genito Urinary System And Sex Hormones | Arterial Calcification; Cardiovascular Calcification; Cardiovascular Disease; End-Stage Kidney Disease (End-Stage Renal Disease or ESRD); Vascular Calcification | Company Press Release |
28 Sep 2019 | Drug Expiry (US) | CSL Ltd | CSL | influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine | Infectious Disease | Influenza A Virus, H1N1 Subtype Infections; Influenza A Virus, H3N2 Subtype Infections; Influenzavirus B Infections | GD Estimates |
01 Sep 2019 | Phase I Trial Initiation | CSL Ltd | CSL | CSL-200 | Hematological Disorders | Sickle Cell Disease | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward